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Changes in hepatitis C virus (HCV) prevalence from 1992 to 2006 were examined by using 24,311 records from
unlinked anonymous surveillance of injecting drug users in England and Wales. Bayesian logistic regression was
used to estimate annual prevalence, accounting for changing recruitment patterns (age, gender, injecting duration,
geographic region, interactions) and the sensitivity and speciﬁcity of different oral ﬂuid testing devices. After
controlling for these differences, the authors found that the adjusted HCV prevalence decreased from 70%
(95% credible interval: 62, 78) in 1992 to 47% (95% credible interval: 43, 51) in 1998 before rising again to 53%
(95% credible interval: 48, 58) in 2006. Women injecting drug users had a higher HCV risk than did men (odds
ratio ¼ 1.50, 95% credible interval: 1.31, 1.73). Two regions (London and North West) had a markedly higher HCV
prevalence than did the rest of England and Wales. Among individuals who had injected for less than 1 year, the
adjusted HCV prevalence in 2006 was higher than that in 1992 (28% vs. 19%, respectively). HCV infection can be
prevented. The public health challenge in England and Wales is to increase action in order to regain a downward
trend in HCV risk and the beneﬁt that has been lost since 1998.
England; hepatitis C; prevalence; sentinel surveillance; substance abuse, intravenous; Wales
Abbreviations: AIC, Akaike Information Criterion; CI, conﬁdence interval; HCV, hepatitis C virus; HIV, human immunodeﬁciency
virus; IDU, injecting drug user.
Hepatitis C virus (HCV) infection is preventable and
treatable. In most developed and transitional countries,
HCV transmission has been concentrated among injecting
drug users (IDUs) (1–4), who typically experience high
rates of infection. For example, in England and Wales, an
estimated 80% of all HCV cases are due to injecting drug
use (5, 6). Preventing infection in this population is thus
a key component of public health responses to reduce
HCV-related harm and morbidity. The main primary inter-
ventions include the provision of sterile injecting equipment
and reducing and stopping injection through opiate substi-
tution therapy (7, 8). Interpreting HCV surveillance data in
order to assess the impact of prevention is complicated by
difﬁculties associated with recruiting representative samples
of IDUs. Although better methods are being developed (9),
most survey data will suffer from recruitment or selection
bias, which needs to be properly accounted for when com-
paring trends in HCV prevalence over time.
Although many studies have reported a high HCV preva-
lence among IDUs, few have reported trends over time, and
these have revealed contrasting pictures. In Australia, the
prevalence of human immunodeﬁciency virus (HIV) is low,
the availability of interventions is good, but HCV preva-
lence remains persistently above 50% and has increased
among recent injectors (10). In Glasgow, Scotland, HCV
prevalence was estimated to have fallen during the early
1990s but remains above 50% (11). In the United States,
evidence for a decrease in HCV prevalence has been found
in a number of cities (Baltimore, Maryland; Los Angeles,
California; and New York, New York) (12, 13).
In this paper, we use surveillance data collected from
approximately 50 sampling sites per year from 1992 to
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trends in HCV prevalence and investigate whether, after
adjustment for changing recruitment patterns (age at test,
gender, injecting duration, geographic region, interactions)
and test accuracy, HCV prevalence has declined.
MATERIALS AND METHODS
The survey
A national unlinked anonymous surveillance of IDUs was
started in 1990 to monitor trends in HIV infection by using
specialist services for IDUs as a pragmatic sampling frame.
Detailed methods have been published elsewhere (14, 15).
Brieﬂy, voluntary oral-ﬂuid samples and an accompanying
questionnaire are collected annually from consenting IDUs
attending representative services across England and Wales
providing needle exchange, opiate substitution therapy, and
treatment for drug use. Since 1998, the samples have been
routinely tested for anti-HCV antibodies, and a recent ex-
tension has allowed retrospective anti-HCV testing of stored
samples from the 1992, 1994, and 1996 surveys. Those aged
15–59 years who had injected in the previous 4 weeks were
included in the analyses in this paper.
Estimatingtrendsinanti-HCVprevalencepresentsanum-
ber of difﬁculties. First, the participating services and their
geographic distribution have changed over time, reﬂecting
changing patterns of drug use and service provision. For
example, in the earlier years, there were many services in
the North West region of England, an area with historically
high rates of HCVinfection among IDUs but also one of the
areas most affected by injecting drug use in the early 1990s
(16, 17). Hence, regional variations in data collection occur
over time and must be adjusted for in the analysis. Second,
the device used to collect oral ﬂuids has also changed over
time, and this affects the sensitivity and speciﬁcity of the
assay in detecting anti-HCV antibodies. Prior to 1998, the
Salivette (Sarstedt, Ltd., Leicester, United Kingdom) collec-
tion device was used in the survey, while from 1998 onward,
the OraSure (OraSure Technologies, Inc., Bethlehem,
Pennsylvania) device has been used. In a population whose
anti-HCV prevalence is 30%, the Salivette device has been
estimated to have a sensitivity of only 74.1% (95% conﬁ-
dence interval (CI): 68.2, 79.4) with 99.0% (95% CI: 97.4,
99.7) speciﬁcity, while the OraSure device has an estimated
sensitivity of 91.7% (95% CI: 87.5, 94.8) and speciﬁcity of
99.2% (95% CI: 97.8, 99.8) (18). Therefore, the sensitivity
of detecting anti-HCV is higher in the 1998–2006 surveys
compared with those conducted before 1998.
This paper uses logistic regression to estimate the shape
of the prevalence trend, while adjusting for variables that
may explain the changing recruitment in unlinked anony-
mous data. The analysis accounts for differential misclassi-
ﬁcation of the infection status; that is, the sensitivity and
speciﬁcity are different for samples collected before and
since 1998. Failure to acknowledge sensitivities and specif-
icities in the analysis would result in an underestimate of
anti-HCV prevalence and a severe underestimation in the
years prior to 1998.
Regression model
A classical logistic regression model is ﬁrst implemented,
with the observed anti-HCV test result as the binary re-
sponse variable. This is regressed against the year in which
the test is taken in order to estimate a period effect. To
account for changing recruitment effects, the following de-
mographic variables are included in the analysis: age, gen-
der, injecting duration, and geographic region of recruitment
(London, Midlands and Wales, North East and Yorkshire,
North West, Southern and Eastern). We do not attempt to
adjust for other variables that may explain the period effect,
for example, injecting risk behaviors. Adjustment for these
variables will dilute the HCV risk trend that we are attempt-
ing to infer.
Nonlinearrelationsareinvestigatedforallcontinuousvari-
ables (year of test, age, injecting duration) through the use of
polynomials. For each variable, the degree of the polynomial
is chosen by selecting the model with the lowest Akaike
Information Criterion (AIC). Polynomial functions up to de-
gree 4 (quartic) were assessed for each continuous variable.
To further improve the ﬁt of the model, all 10 possible 2-way
interactions of the 5 variables are considered. Variable selec-
tion is performed, and the model with the lowest AIC is
chosen. A global goodness-of-ﬁt test for the ﬁnal binary lo-
gistic model is performed by using the method proposed by
le Cessie and van Houwelingen (19). To judge the effect of
missing data on model estimates, we conducted multiple
imputation using chained equations (20) in a sensitivity anal-
ysis. The prevalence trend estimated from the ﬁnal model
is plotted over the study period by setting all other covariates
to their mean values in the data set.
Prevalence in recent initiates (those with injecting dura-
tion of <1 year) is strongly associated with HCVincidence,
and hence we also considered an additional model where
injecting duration is expressed as a binary variable (recent
vs. nonrecent initiates).
Accounting for imperfect sensitivity and speciﬁcity of
the test device
As discussed above, the anti-HCV test sensitivity and
speciﬁcity are not perfect and differ over time as the result
of a change in the testing device. From the law of total
probability, a positive test result occurs with probability,
p ¼ p Sens þð 1   pÞð1   SpecÞ;
where p is the true prevalence of disease, and ‘‘Sens’’ and
‘‘Spec’’ are the sensitivity and speciﬁcity of the test, respec-
tively. If the sensitivity and speciﬁcity are known exactly,
then one can estimate the true probability of disease from
the observed test results. Magder and Hughes (21) suggest
an expectation-maximization algorithm to do this in the
context of logistic regression.
In this setting, the sensitivity and speciﬁcity of the assay
using the 2 collection devices are not known exactly, and we
wish to incorporate this uncertainty in the model. Their
estimated values together with 95% conﬁdence intervals
are given above and as reported by Judd et al. (18). To
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is implemented with the same choice of variables as from
the best-ﬁtting classical logistic model. The sensitivity and
speciﬁcity of each device are given informative prior prob-
ability distributions to reﬂect the uncertainty surrounding
their values. To achieve this, the log-odds of both ‘‘Sens’’
and ‘‘Spec’’ are assumed to follow normal distributions with
means equal to the log-odds of the estimated values, and
variances were calculated from the corresponding conﬁ-
dence intervals. Regression parameters in the logistic model
are given noninformative prior distributions, and inferences
are made from the posterior distributions of these param-
eters. A similar approach is described in detail by McInturff
et al. (22). The Bayesian analysis provides a posterior dis-
tribution for each parameter of the logistic model and,
hence, a posterior distribution for the predicted HCV prev-
alence from each combination of covariate values and for
differences in HCV prevalence between subgroups. This, in
turn, allows calculation of posterior probabilities of any
quantity of interest, for example, the difference between
HCV prevalence in 2006 compared with that in 1992.
Implementation
All classical analyses were carried out by using the
‘‘glm’’ function in R. Bayesian analyses were performed
by using Markov chain-Monte Carlo techniques imple-
mented in WinBUGS (23), and for which the model code
is available from the authors upon request. Inferences were
based on 32,000 iterations from 2 chains running in parallel,
and convergence was assessed through the use of the
Brooks-Gelman diagnostic (24).
RESULTS
In total, 24,311 participations were available from Eng-
land and Wales over the years 1992, 1994, 1996, and 1998–
2006. Appendix Table 1 in the Appendix shows the ob-
served number and proportion testing positive for anti-
HCV by year, sex, region, injecting duration, and age.
The ﬁnal classical logistic regression model (with the
lowest AIC) included all main effects and six 2-way inter-
actions (year of test 3 region, year of test 3 injecting dura-
tion, region 3 injecting duration, region 3 gender, region 3
age, gender 3 injecting duration). The main effects of the
continuous covariates, year of test and injecting duration,
were found to be best modeled by use of cubic polynomials,
while age was found to be best modeled by use of a qua-
dratic. The ﬁnal model showed a good ﬁt to the data (global
test for lack ofﬁt, P ¼ 0.862). Parameter estimates from this
model are shown in the Appendix (Appendix Table 2).
There were 1,087 (4.5%) individuals missing information
on injecting duration, 504 (2.1%) missing HCV test status,
465 (1.9%) missing age, 140 (0.6%) missing gender, and 2
(0.008%) missing region of recruitment. All individuals
missing anti-HCV test status were from participations in
1992, 1994, or 1996 (stored sample either could not be
located or was insufﬁcient for testing). A multiple imputa-
tion analysis was undertaken, and results were almost iden-
tical to those from the complete case analysis (results not
shown but available on request); therefore, the ﬁndings from
the unimputed analyses are reported here.
Figure 1 shows the change in estimated prevalence from
the Bayesian logistic model before and after accounting for
the sensitivity and speciﬁcity of the oral-ﬂuid test.
Figure 1. Estimated hepatitis C virus (HCV) antibody prevalence trend for injecting drug users before and after accounting for test device
sensitivities and speciﬁcities, England and Wales, 1992–2006. All other covariates are set to their mean values. Dashed lines show 95% credible
intervals for the model accounting for device misclassiﬁcation. Dotted lines show 95% credible intervals for the model not accounting for device
misclassiﬁcation.
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fect of increasing the estimated prevalence, especially be-
fore 1998, when the sensitivity was lower. The uncertainty
surrounding the estimated prevalence also increases to ac-
count for the uncertainty in the level of test sensitivity and
speciﬁcity. In Figure 1, the estimated prevalence is shown,
with all the other variables set to their mean levels, and can
therefore be interpreted as the average adjusted prevalence
in the study population. Results suggest that the adjusted
HCV prevalence among IDUs decreased from 70% (95%
credible interval: 62, 78) in 1992 to 47% (95% credible
interval: 43, 51) in1998, beforeslowly rising again to alevel
of 53% (95% credible interval: 48, 58) in 2006. Using this
predicted trend, we estimate a 99.9% chance that the HCV
prevalence in 2006 is greater than that in 1998.
Table 1 shows the odds ratio of HCVinfection for region,
gender, injecting duration, and age, when all other covari-
ates are at their mean level. After adjustment, there is evi-
dence for higher HCV prevalence among female IDUs than
among males (odds ratio ¼ 1.50, 95% credible interval:
1.31, 1.73). HCV prevalence also increases with injecting
duration, with the odds ratio for those injecting for 5 years
compared with <1 year estimated as 2.84 (95% credible
interval: 2.47, 3.38).
Figure 2 shows the estimated prevalence trends from the
model in which individuals are classiﬁed as recent and non-
recent initiates. Results reveal a comparatively high HCV
adjusted prevalence in individuals who have injected for less
than 1 year—at 19% (95% credible interval: 10, 34) in 1992
approximately halving by 1998 and then increasing to 28%
(95% credible interval: 17, 41) in 2006. The increase from
1998 has been more marked in recent than nonrecent ini-
tiates. The probability that HCV prevalence is higher in
2006 than in 1992 for recent initiates is estimated as 83.9%.
Strong regional effects are identiﬁed, and Figure 3 shows
the estimated prevalence trend by geographic region. HCV
prevalence in London and the North West is markedly
higher than in the other regions and, by 2006, had risen on
average to 70%. In London, there is an 8.3% probability that
prevalence in 2006 is as high as it was in 1992. The trends
from the other regions all overlap, with the estimated prev-
alence especially uncertain in the early years (because of
small samples from some areas), and in general suggest that
HCV risk fell in the early 1990s and from 1998 ﬂattenedout.
Analyses that further subdivided the regions in the rest of
England and Wales (without London and the North West
region) gave a similar picture but also increased the uncer-
tainty surrounding the average estimates (results not
shown).
The effect of age on the risk of HCV infection is pre-
sented in Table 1 for selected ages. Despite adjustment for
injecting duration, so that at each age the average duration is
the same, there is still a clear age effect, with older individ-
uals having a higher risk of infection than younger IDUs.
DISCUSSION
Our analysis of public health surveillance data suggests
that, in England and Wales, HCV risk prevalence among
IDUs declined during the 1990s but that the trend reversed
after 1998 such that, in 2006 in some areas and among some
subgroups of IDUs, HCV prevalence was approaching or
even greater than that in 1992. In addition, we suggest that,
in England and Wales, marked geographic differences in
HCV prevalence remain, and prevalence among recent in-
jectors of <1 year has increased rapidly since 1998 and is
higher than the HCV prevalence in 1992. This is consistent
with results from some studies in the United Kingdom that
suggest increased HCV prevalence among recent initiates
(25, 26) and that any change in HCV risk would occur more
quickly among recent injectors. In our models, the risk of
infection was estimated to increase monotonically with in-
jecting duration, after adjustment for age and year of test
(i.e., any cohort effect). This is to be expected, because the
risk of current or past infection, as measured through anti-
HCV antibodies, can only accumulate with exposure.
We found that, even after adjustment (for age, injecting
duration, and year of test), women are more likely to be
infected than men, and older injectors with the same average
injecting duration are more likely to be infected than youn-
ger injectors. In contrast, a recent meta-analysis of HCV
prevalence studies reportedno signiﬁcant difference in prev-
alence between men and women (27). The difference in
HCV prevalence risk experienced by older injectors may
be due to residual cohort effects that have not fully been
accounted for or, alternatively, may reﬂect differential
Table 1. Multivariate Bayesian Model of Hepatitis C Virus Infection
Risk for Injecting Drug Users, England and Wales, 1992–2006
Variable Odds Ratio
a 95% Credible
Interval
Region
London 1.00
Midlands and Wales 0.47 0.39, 0.57
North East and Yorkshire 0.45 0.36, 0.55
North West 1.67 1.41, 2.01
Southern and Eastern 0.37 0.31, 0.44
Gender
Male 1.00
Female 1.50 1.31, 1.73
Injecting duration, year(s)
<1 1.00
1 1.27 1.23, 1.34
5 2.84 2.47, 3.38
10 6.84 4.99, 9.99
15 9.11 7.39, 11.80
Age, years
20 1.00
30 1.63 1.44, 1.85
40 2.33 1.98, 2.76
50 2.90 2.23, 3.91
a Odds ratios are presented for the mean characteristics of the
study population.
Hepatitis C Infection Among Injecting Drug Users 355
Am J Epidemiol 2009;170:352–360exposure to other injectors with a higher risk of HCV. Dif-
ferential exposure could also explain why we found a higher
adjusted prevalence in females. That is, women may tend to
inject with older men with a longer injecting duration and
therefore are at greater risk of exposure to HCV. Such a pat-
tern has been observed in a network of New York IDUs (28).
An alternative hypothesis is that women also may be more
vulnerable and may be less able to control their injecting
environment and risk than men (29–31). Equally, people
who start injecting at an older age (after 25 years) may
have greater comorbidity and/or other risks, such as home-
lessness and prison history, that increase their HCV risk,
or there may be a greater misclassiﬁcation of injecting
duration among older injectors. These hypotheses and
Figure 3. Estimated hepatitis C virus (HCV) antibody prevalence trend for injecting drug users by region, England and Wales, 1992–2006. All
other covariates are set to their mean values. Error bars show 95% credible intervals for each region.
Figure 2. Estimated hepatitis C virus (HCV) antibody prevalence trend for injecting drug users by recent and nonrecent initiates, England and
Wales, 1992–2006. All other covariates are set to their mean values. Error bars show 95% credible intervals.
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targeted prevention.
Strengths and limitations
Two key strengths of this work are the sources of data and
analytical approach. First, the data were obtained from an
ongoing surveillance program that has recruited reasonably
sized (n   2,000) annual samples by using the same meth-
odology over time, although the service provision from
which samples are drawn has necessarily changed over the
time period. Second, we deployed innovative statistical
methodology to adjust for changes in the accuracy of the
testing device by allowing uncertainty in the knowledge of
the level of sensitivity and speciﬁcity in the adjustment pro-
cess. We also modeled age and injecting duration as contin-
uous variables using polynomials. This approach provides
a better ﬁt to the relation between age/duration of injecting
and HCV risk, which is not linear, and reduces the number
of parameters compared with introducing categorical data
(16).
The resulting estimated HCV prevalence overall and
among subgroups is based on the average characteristics
of the sample, and therefore the emphasis of this work is
on relative changes in HCV risk over time, which we feel
are more readily interpretable and the appropriate focus of
routine surveillance. However, the estimates do not provide
direct information on the true HCV prevalence in the IDU
population, which can be addressed only if we assumed that
we had recruited a representative sample of IDUs or had
external information to generate speciﬁc sample weights
that could be applied to the routine surveillance data. Such
an assumption is not warranted, and data for the latter are
unavailable.
We acknowledge several related limitations. First, al-
though we sampled from similar sites (n   50 low threshold
treatment and syringe exchanges) each year, these have
changed over time broadly reﬂecting changes in service
provision. The changes in distribution and types of services
provided will, in part, reﬂect changing patterns of drug use
and the types of drug being used, as well as developments in
drug policy, such as expanded provision of specialist drug
treatment. Although we adjusted for several potential con-
founders, it is possible that the case-mix and other unmea-
sured factors (such as severity of dependence, proportion of
former prisoners, and quicker access to treatment) relating
to HCV risk have also changed over time.
Second, we lacked power and continuous surveillance
data to investigate a more reﬁned classiﬁcation of geo-
graphic areas. There are cities in the deﬁned geographic
regions (such as Bristol and Brighton in the Southern and
Eastern region and Leeds in the North East and Yorkshire
region) that have higher levels of HCV than other cities,
towns, and rural areas in these regions (16). Preliminary
investigations suggested that, in the Southern and Eastern
region, the proportion of high prevalence sampling sites did
not remain constant over time. However, further analyses
subdividing this region into ‘‘high,’’ ‘‘medium,’’ and ‘‘low’’
prevalence sites found a generally consistent overall picture
of trend (data not shown).
Third, we do not attempt to explain the differences in
HCV prevalence, for example, by ﬁtting additional covari-
ates on injecting risk behavior or the availability and inten-
sity of prevention services. In part, this is because full data
on risk behavior and other predictors are unavailable, but
primarily because the main purpose of our analyses was to
provide basic public health evidence on whether HCV risk
(as measured by estimated anti-HCV prevalence) has
changed over time.
Our work attempts to estimate trends in HCV prevalence
and models prevalence in recent (<1 year) injectors as
a measure of incidence, but another possible approach
would be to estimate incidence directly from serial preva-
lence and exposure information (e.g., refer to references 32
and 33). These approaches directly address issues concern-
ing incidence and transmission. Nevertheless, results from
our model still provide useful information concerning the
underlying epidemic among IDUs.
Interpretation—public health intelligence
There are 2 key messages for policy makers and practi-
tioners in England and Wales and elsewhere. First, HCV
among IDUs can be controlled: There are some places with
low HCV prevalence and HCV risk fell during the early to
mid-1990s, even in sites with a high background prevalence
of HCV. The declines in risk support the hypothesis that the
health education, needle exchange, and opiate substitution
treatment widely used in the United Kingdom in the late
1980s changed behavior and injecting risk for HCVas well
as HIV infection among IDUs (34–36).
Second, increased action and prevention services are re-
quired. Since 1998, HCV risk has remained stable or in-
creased and, among some IDUs (particularly recent
injectors), any beneﬁts of the risk reduction achieved in
earlier years have been lost. There are several potential
and overlapping reasons for the increase in risk that cannot
be explored by these data alone. These include increases in
the prevalence of injecting over and above any increase in
prevention services (37, 38) and/or changes in the character-
istics of the IDU population (such as increased homeless-
ness and crack-cocaine injection) that may have led to
increased injecting risk (16). Whatever the explanation,
and it is likely to be a combination of reasons, the key public
health challenge is to reverse the currently rising HCV risk
through increasing effective intervention coverage (8, 39,
40). The challenge to our public health surveillance program
is to improve information collected on the characteristics
of IDUs so that we can develop better models of HCV risk
in order to inform and measure the impact of public health
action.
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Appendix Table 1. Observed Hepatitis C Virus Antibody Prevalence by Covariate Level,
England and Wales, 1992–2006
Variable No. Positive No. Tested Proportion Positive
Year of test
1992 850 1,800 0.47
1994 868 2,134 0.41
1996 640 1,810 0.35
1998 896 2,306 0.39
1999 830 2,485 0.33
2000 791 2,362 0.33
2001 716 2,063 0.35
2002 741 1,819 0.41
2003 743 1,693 0.44
2004 704 1,572 0.45
2005 824 1,828 0.45
2006 824 1,935 0.43
Sex
Male 7,196 18,162 0.40
Female 2,171 5,510 0.39
Region
London 2,329 4,418 0.53
Midlands and Wales 865 2,868 0.30
North East and Yorkshire 611 2,999 0.20
North West 3,254 6,089 0.53
Southern and Eastern 2,368 7,431 0.32
Injecting duration, years
0–4 1,619 7,897 0.21
5–9 2,201 6,077 0.36
10–14 2,008 4,032 0.50
 15 3,119 4,755 0.66
Age, years
15–24 1,155 5,773 0.20
25–29 2,071 6,100 0.34
30–34 2,381 5,331 0.45
35–59 3,600 6,158 0.58
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Injecting Drug Users, England and Wales, 1992–2006
Parameter Estimate Standard Error z Value P Value
Intercept  0.105 0.058  1.82 0.069
Year of test
Linear 0.081 0.012 6.57 <0.001
Quadratic 0.0045 0.0022 2.05 0.041
Cubic  0.00112 0.00026  4.38 <0.001
Age, years
Linear 0.0124 0.0066 1.87 0.061
Quadratic  0.00069 0.00027  2.52 0.012
Gender, females 0.262 0.085 3.07 0.002
Injecting duration, years
Linear 0.1131 0.0072 15.79 <0.001
Quadratic  0.00394 0.00061  6.48 <0.001
Cubic 0.000061 0.000025 2.43 0.015
Region, baseline London
Midlands and Wales  0.593 0.085  6.97 <0.001
North East and Yorkshire  0.713 0.095  7.54 <0.001
North West 0.404 0.069 5.83 <0.001
Southern and Eastern  0.876 0.070  12.42 <0.001
Gender 3 injecting duration
Females 3 linear effect  0.0169 0.0080  2.13 0.033
Females 3 quadratic effect  0.0036 0.0012  3.12 0.002
Females 3 cubic effect 0.000190 0.000063 2.99 0.003
Injecting duration 3 region
Linear 3 Midlands and Wales  0.014 0.010  1.35 0.178
Linear 3 North East and Yorkshire 0.039 0.013 2.97 0.003
Linear 3 North West  0.0230 0.0082  2.79 0.005
Linear 3 Southern and Eastern 0.0064 0.0078 0.83 0.409
Year of test 3 injecting duration
Linear 3 linear  0.00142 0.00075  1.91 0.057
Quadratic 3 linear  0.00084 0.00017  5.02 <0.001
Linear 3 quadratic 0.000110 0.000061 1.82 0.069
Quadratic 3 quadratic 0.000028 0.000014 1.98 0.048
Year of test 3 region
Linear 3 Midlands and Wales  0.039 0.015  2.63 0.009
Linear 3 North East and Yorkshire  0.057 0.025  2.29 0.022
Linear 3 North West  0.000 0.012  0.00 0.999
Linear 3 Southern and Eastern  0.055 0.011  4.91 <0.001
Quadratic 3 Midlands and Wales  0.0045 0.0033  1.35 0.177
Quadratic 3 North East and Yorkshire  0.0043 0.0052  0.82 0.413
Quadratic 3 North West  0.0036 0.0026  1.39 0.164
Quadratic 3 Southern and Eastern 0.0046 0.0026 1.75 0.079
Age 3 region
Linear 3 Midlands and Wales 0.025 0.011 2.40 0.017
Linear 3 North East and Yorkshire  0.002 0.012  0.20 0.841
Linear 3 North West 0.0268 0.0084 3.17 0.002
Linear 3 Southern and Eastern 0.0381 0.0082 4.63 <0.001
Gender 3 region
Females 3 Midlands and Wales  0.16 0.13  1.19 0.233
Females 3 North East and Yorkshire 0.04 0.15 0.28 0.777
Females 3 North West  0.01 0.10  0.13 0.894
Females 3 Southern and Eastern 0.25 0.10 2.49 0.013
Abbreviation: AIC, Akaike Information Criterion.
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